Skip to main content
Clinical Trials/NCT03231956
NCT03231956
Unknown
N/A

Noninvasive Hemodynamic Monitoring Utilizing ClearSight TM System in Suspected Sepsis Patients Presenting to the Emergency Department (CLEAR SEPSIS)

Edwards Lifesciences5 sites in 1 country182 target enrollmentJune 29, 2017
ConditionsSepsis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sepsis
Sponsor
Edwards Lifesciences
Enrollment
182
Locations
5
Primary Endpoint
Venous Blood Lactate clearance
Last Updated
6 years ago

Overview

Brief Summary

To investigate the relationship between initial ClearSight™ derived hemodynamic parameters and outcomes (death, ongoing organ dysfunction or delayed ICU admission) in patients with acute infection and possible sepsis, with a focus on venous blood lactate (< 2.0, 2.0-3.9, and ≥ 4.0 mmol/dL) and hemodynamic subgroups, using ED patients presenting with minor infections or asthma/COPD exacerbations as controls (henceforth referred to as Sepsis Mimic Group).

Registry
clinicaltrials.gov
Start Date
June 29, 2017
End Date
June 30, 2022
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Edwards Lifesciences
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ≥ 18 years of age at the time of enrollment
  • Any combination of acute symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection
  • ED Physician confirms likely hospital admission (\> 50%) due to suspicion of infection
  • ED Physician confirms intention to order both blood cultures and venous blood lactate levels
  • Ability to enroll patient and begin ClearSight™ monitoring within three (3) hours of ED presentation

Exclusion Criteria

  • Initial venous blood lactate measured \> 3 hours after ED arrival
  • Pre-existing infection for which patient is being treated with antibiotics as an outpatient
  • Prisoners
  • Pregnant women
  • Any previous medical condition with life expectancy of \< 3 months (patients with ESRD and heart failure are not excluded)
  • DNR or comfort care order preexisting to ED visit or established in the ED
  • Palliative care or hospice consult in the ED
  • Known severe aortic insufficiency
  • Known history of Raynaud's disease
  • Poor follow-up candidate in the opinion of the Investigator

Outcomes

Primary Outcomes

Venous Blood Lactate clearance

Time Frame: Within 24 and 72 hours of presentation

Venous Blood Lactate clearance

Composite outcome

Time Frame: Within 72 hours of presentation

Increase in modified Sequential Organ Failure Assessment (mSOFA) score ≥ 1 resulting in ICU admission / death.

Length of Stay

Time Frame: 30 days

Emergency Department length of stay, ICU length of stay, and Hospital length of stay

Recidivism

Time Frame: 30 days

Recidivism within 30 days of the index hospital visit

Study Sites (5)

Loading locations...

Similar Trials